Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Depotech(depo) -- Ignore unavailable to you. Want to Upgrade?

To: Dr. John M. de Castro who wrote (867)	11/17/1998 10:20:00 AM
From: Sector Investor	Read Replies (1) \| Respond to of 887

"The terms of the contingent payment provide that DepoTech shareholders will receive approximately 1.5 million additional SkyePharma ADS's if DepoTech's lead product, DepoCyt(TM), an anticancer drug, is launched in the U.S. no later than March 31, 2000. Further, DepoTech shareholders will receive approximately 1.2 million additional SkyePharma ADS's if a development agreement is signed with a corporate partner for either DepoMorphine(TM) or a macromolecule program." Apparently approval is not the same as launching in the U.S, as the additional shares don't appear to be factored in? Or am I reading it wrong? Is there a play here based on this? Oops, it looks like the price is moving up.